Celon Pharma S.A. (WSE:CLN)

Market Cap	1.22B -5.6%
Revenue (ttm)	225.60M +7.3%
Net Income	-122.39M
EPS	-2.36
Shares Out	53.86M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,287
Average Volume	13,194
Open	21.80
Previous Close	22.70
Day's Range	21.50 - 22.20
52-Week Range	18.50 - 28.65
Beta	0.68
RSI	53.29
Earnings Date	Apr 22, 2026

About Celon Pharma

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of pharmaceutical products and preparations. It offers drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. operates as a subsidiary of Glatton Sp. z o.o.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 566
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: CLN

Financial Performance

In 2024, Celon Pharma's revenue was 205.55 million, a decrease of -4.25% compared to the previous year's 214.66 million. Losses were -34.45 million, 22.5% more than in 2023.